Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder

Table 2 The relationship between HMGA2 and CD9 expression and clinicopathological features of gallbladder cancer

Clinical and pathological features	Case Number	HMGA2			CD9
		Positive Number(%)	χ ²	P	Positive Number(%)	χ ²	P
Gender
Male	24	15(62.5)	0.13	>0.05	11 (45.8)
Female	84	49(58.3)	0.13	>0.05	46 (54.8)	0.60	>0.05
Age (years)
≤45	31	16(51.6)	1.05	>0.05	15 (48.4)	0.34	>0.05
>45	77	48(62.3)	1.05	>0.05	42 (54.5)	0.34	>0.05
Pathological types *
Well differentiated	36	12(33.3)	16.38	<0.01	26 (72.2)	10.26	<0.05
Differentiated	31	21(67.7)			15 (48.4)
Poorly differentiated	30	24(80.0)			10 (33.3)
Mucinous adenocarcinoma	11	7(63.6)			6 (54.5)
Tumor maximum diameter (cm)
<2	31	14(45.2)	3.70	<0.05	22 (71.0)	5.77	<0.05
≥2	77	50(64.9)	3.70	<0.05	35 (48.6)	5.77	<0.05
Lymph node metastasis
No	49	22(44.9)	7.66	<0.01	34 (69.4)	9.93	<0.01
Yes	59	42(61.2)	7.66	<0.01	23 (39.0)	9.93	<0.01
Violations of the surrounding tissues
No	49	21(42.9)	9.99	<0.01	33 (67.3)	7.64	<0.01
Yes	59	43(62.9)	9.99	<0.01	24 (40.7)	7.64	<0.01
Gallbladder stones
No	50	25(50.0)	3.31	>0.05	24 (48.0)	0.85	>0.05
Yes	58	39(67.2)			33 (56.9)

*Comparison between well-differentiated and differentiated adenocarcinoma: χ²HMGA2 = 7.89, P <0.01; χ²CD9 = 3.98, P <0.05.
*Comparison between well-differentiated and poorly-differentiated adenocarcinoma:
χ²HMGA2 = 14.37, P <0.01; χ²CD9 = 9.98, P <0.01.

ISSN: 1477-7819